Search results
Merck Lifts FY24 Outlook After Higher Q1 Earnings, Above Market; Stock Up In Pre-market
RTT News· 6 days agoDrug major Merck & Co., Inc. (MRK), while reporting higher first-quarter earnings, above market estimates, on Thursday raised its fiscal 2024 adjusted earnings and sales view.
We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt
Simply Wall St. via Yahoo Finance· 6 days agoSo it might be obvious that you need to consider debt, when you think about how risky any given...
Pfizer’s first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Market Watch· 11 hours agoAn expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 6 days agoZacks Rank & Stocks to Consider Merck currently has a Zacks Rank #3 (Hold). Merck & Co., Inc. Price...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 6 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 5 days agoOn Friday, Wells Fargo adjusted its outlook on shares of pharmaceutical giant Merck & Co., Inc....
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 2 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Reuters· 6 days ago, opens new tab on Thursday raised its annual profit and revenue forecast on the back of strong...
20 Fastest Growing Health Tech Companies in the World
Insider Monkey via Yahoo Finance· 6 days agoIn this article, we will be taking a look at the 20 fastest growing health tech companies in the...
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points - Chevron (NYSE:CVX),...
Benzinga· 6 days agoThe U.S. economy grew an annualized 1.6% in the first quarter, marking a notable slowdown from the 3.4% rate in the final quarter of 2023. Merck & Co., ...